A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia

Yixuan Ma, Luyang Chang, Lin Wang, Lin Chen, Xudong Wei, Ruihua Mi · 2026

Read A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia by Yixuan Ma, Luyang Chang, Lin Wang, Lin Chen, Xudong Wei, Ruihua Mi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13540810.txt.

Description

Yixuan Ma and five colleagues review, in a 2026 single-centre study, short-term results of blinatumomab for high-risk B-cell acute lymphoblastic leukaemia in China. The drug links T cells to leukaemia cells bearing CD19, and trial success needed real-world confirmation in this harder-to-treat group.

Twenty-nine patients received cycles lasting one to four weeks. After a single cycle, measurable residual disease had vanished in about eighty-three percent of patients. Every patient with the Ph-like subtype cleared disease, while results weakened sharply for two genetic patterns: a T315I change in the BCR::ABL1 fusion and an E2A::PBX1 rearrangement. Serious blood toxicity touched nearly half the cohort.

Catalog record

CREATORYixuan Ma, Luyang Chang, Lin Wang, Lin Chen, Xudong Wei, Ruihua Mi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32067
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13540810

Browse the full library · About the Tower of Babel